/NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S.
WIRE SERVICES/
WINNIPEG, Dec. 1, 2017 /CNW/ - DELTA 9 CANNABIS INC. (TSXV:
NINE) ("Delta 9" or the "Company") is pleased to announce the appointment of Joanne Duhoux-Defehr
to the board of directors of Delta 9.
Ms. Duhoux-Defehr is President of Triple D Developments Ltd., where she managed 1.5 million square feet of commercial and
industrial buildings, including the building that houses Delta 9's production facility. Ms. Duhoux-Defehr earned a BA in Business
Administration and a degree in Theology in the Netherlands, and a law degree from the
University of San Francisco.
Ms. Duhoux-Defehr initially worked in the area of business litigation and intellectual property in the US as a member of the
California bar. She currently sits on the board of several companies, and is a core founding
member of the Delta 9 team. Ms. Duhoux-Defehr sat on the board of Delta 9 Bio-Tech Inc. (now a subsidiary of the Company) prior
to its merger with SVT Capital Corp. (now the Company) in October this year, and now joins the board of Delta 9.
"We're very excited to officially welcome Joanne to the Delta 9 board, but in truth she has always been a key member of our
team," said Delta 9 CEO John Arbuthnot. "Joanne was one of our early supporters, one of our first
major investors, and has helped tremendously in the Company's growth through her deep knowledge of commercial real estate and
legal issues."
Ms. Duhoux-Defehr, as President of Triple D Developments Ltd., was pivotal in negotiating and arranging for the development of
the current Delta 9 production facility in Winnipeg, Mr. Arbuthnot added.
"Joanne's role in our Company's success thus far cannot be underestimated," said Mr. Arbuthnot. "But she remains equally
important as Delta 9 moves into the next phase of our expansion."
Ms. Duhoux-Defehr says she is very pleased to join the board of Delta 9 given her long association with its founders, the
father and son team of Delta 9 President Bill Arbuthnot and CEO John
Arbuthnot.
"I am fascinated by disruptive industries, and there are few opportunities in anyone's life to take part in an entirely new
industry that is being built from the ground up, so I feel very privileged to be part of the Delta 9 team," Ms. Duhoux-Defehr
said. "But you don't just invest in an industry or a company; you invest in the people who operate that company. I have known
Bill and John for many years now and I've been incredibly impressed with their work ethic, their innovative approach to this
business, and their ability to make good use of capital."
Ms. Duhoux-Defehr is the fifth member of the board of directors of Delta 9. She joins fellow directors John Arbuthnot, Anthony Jackson, and Nitin
Kaushal, and board Chair Bill Arbuthnot.
About Delta 9 Cannabis Inc.
Delta 9's wholly-owned subsidiary, Delta 9 Bio-Tech Inc., is a licensed producer of medical marijuana pursuant to the ACMPR and
operates an 80,000 square foot production facility in Winnipeg, Manitoba, Canada. Delta 9's
shares trade on the TSX Venture Exchange under the symbol "NINE".
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies
of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Disclaimer for Forward-Looking Information
Certain statements in this release are forward-looking statements, which reflect the expectations of management regarding
the Company's future business plans and other matters. Forward-looking statements consist of statements that are not purely
historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Forward looking
statements in this news release include statements relating to Delta 9's future expansion. Such statements are subject to risks
and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the
statements, including that Delta 9's currently contemplated expansion and development plans may cease or otherwise change, Delta
9's production of cannabis may be lower than expected, Delta 9 may not obtain the required approvals from Health Canada, demand
for Delta 9's products may be lower than anticipated, Delta 9's cost to produce its grow pods may be higher than expected and all
other risk factors set forth in the filing statement of Delta 9 dated October 25, 2017 which has
been filed on SEDAR. No assurance can be given that any of the events anticipated by the forward-looking statements will occur
or, if they do occur, what benefits the Company will obtain from them. Readers are urged to consider these factors carefully in
evaluating the forward-looking statements contained in this news release and are cautioned not to place undue reliance on such
forward-looking statements, which are qualified in their entirety by these cautionary statements. These forward-looking
statements are made as of the date hereof and the Company disclaims any intent or obligation to update publicly any
forward-looking statements, whether as a result of new information, future events or results or otherwise, except as required by
applicable securities laws.
SOURCE Delta 9 Bio-Tech
View original content with multimedia: http://www.newswire.ca/en/releases/archive/December2017/01/c4042.html